TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6734028

Group type: EXPERIMENTAL
Intervention: 400 micrograms fenoterol by metered dose inhaler four times a day
Number of subjects: 8

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 8
Study: 31352679

Group type: EXPERIMENTAL
Intervention: Prophylactic dose of low-molecular-weight heparin
Number of subjects: 1519

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 1519

Group type: EXPERIMENTAL
Intervention: L-TRiP(cast) score
Number of subjects: 1519
Study: 29734920

Group type: EXPERIMENTAL
Intervention: Boston University approach to psychiatric rehabilitation
Number of subjects: 156

Group type: COMPARATOR
Intervention: Generic approach to psychiatric rehabilitation
Number of subjects: 156
Study: 26767612

Group type: EXPERIMENTAL
Intervention: Portion size increased to 200% of baseline amounts
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medium-energy density foods
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-energy density foods
Number of subjects: 48
Study: 24812432

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 446
Study: 22900989

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day) for 6 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Change in peripheral leukocyte count
Number of subjects: 32
Study: 19858319

Group type: EXPERIMENTAL
Intervention: Transdermal TPTD patch (20, 30, or 40-microg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Transdermal TPTD 40-microg patch
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: All treatment groups (including transdermal TPTD and TPTD injection)
Number of subjects: 165
Study: 17661854

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily (BID)
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 1139

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study: 16109730

Group type: EXPERIMENTAL
Intervention: Unsupported reference arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supported reference arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexion or extension conditioning of the reference arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unsupported and weighted reference arm
Number of subjects: 0
Study: 12592679

Group type: EXPERIMENTAL
Intervention: Estrogen treatment (n = 24)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chinese nourishing Kidney herbs (CNKH) (n = 32)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 56
Study: 10080199

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 33

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 33
Study: 7593097

Group type: EXPERIMENTAL
Intervention: Core decompression
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 37
Study: 2179038

Group type: EXPERIMENTAL
Intervention: Cetacaine topical anesthetic spray preparation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 7363933

Group type: EXPERIMENTAL
Intervention: Disopyramide capsules 150 mg every 6 h for five days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Controlled-release tablets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Disopyramide capsules
Number of subjects: 10
Study: 31442618

Group type: EXPERIMENTAL
Intervention: Lifestyle and occupational exposures (including age, BMI, cigarette smoking, regular exercise, daily vehicle vibration)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Univariate regression analyses
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Occupational loading measurements
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Multivariate regression analyses
Number of subjects: 644
Study: 31429418

Group type: EXPERIMENTAL
Intervention: Self-monitoring (SM)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 122
Study: 27492865

Group type: EXPERIMENTAL
Intervention: Low GL diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low Fat diet
Number of subjects: 22
Study: 26854207

Group type: EXPERIMENTAL
Intervention: Expectation survey reviewed by clinician
Number of subjects: 304

Group type: COMPARATOR
Intervention: Expectation survey not reviewed (Control group)
Number of subjects: 304

Group type: COMPARATOR
Intervention: No expectation survey (Baseline group)
Number of subjects: 304
Study: 24952697

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 5011

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5011
Study: 22420645

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) with intrathecal bupivacaine 2.5 mg and fentanyl 5 μg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Epidural with bupivacaine 20 mg and fentanyl 40 μg
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 115
Study: 20637249

Group type: EXPERIMENTAL
Intervention: Topiramate plus risperidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 40
Study: 17895472

Group type: EXPERIMENTAL
Intervention: High-dose sorafenib
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15863745

Group type: EXPERIMENTAL
Intervention: Staff training programme
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 10
Study: 12036673

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9880383

Group type: EXPERIMENTAL
Intervention: Clomethiazole (75 mg/kg)
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Clomethiazole
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Clomethiazole (in TACS subgroup)
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Placebo (in TACS subgroup)
Number of subjects: 1360
Study: 7485006

Group type: EXPERIMENTAL
Intervention: Through-the-scope manometry
Number of subjects: 12

Group type: COMPARATOR
Intervention: Laboratory testing
Number of subjects: 12
Study: 2023212

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 148

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 148
Study: 7130643

Group type: EXPERIMENTAL
Intervention: Continuations of repetitions (AAAAA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Discontinuations of alternations (BBBBA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: P300 latencies for elderly women
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mean reaction time
Number of subjects: 20
Study: 31627723

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham MWM
Number of subjects: 40
Study: 28870107

Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study: 26590130

Group type: EXPERIMENTAL
Intervention: Qigong exercise (60-min sessions, 3 times per week for 3 months)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 145
Study: 25157992

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and surgery (case group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 22
Study: 22067237

Group type: EXPERIMENTAL
Intervention: Motivational music
Number of subjects: 20

Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 20
Study: 19349341

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Number of subjects: 14
Study: 17487652

Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol (E2) + 0.25 mg norethisterone acetate (NETA)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 0.5 mg E2 + 0.1 mg NETA
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 15519264

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12901541

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Granisetron (3 mg)
Number of subjects: 111
Study: 11578015

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (200 microg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9635933

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily for 3 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg twice daily for 3 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 22
Study: 7880946

Group type: EXPERIMENTAL
Intervention: 16-session biofeedback training with visual and auditory feedback
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Labile group (23 subjects)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stabile group (17 subjects)
Number of subjects: 40
Study: 3275894

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg every six hours)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 8235685

Group type: EXPERIMENTAL
Intervention: Adhesive, non-elastic tape
Number of subjects: 112

Group type: COMPARATOR
Intervention: Confection brace
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 112
Study: 849673

Group type: EXPERIMENTAL
Intervention: Thioridazine (high dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Thioridazine (low dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Thioridazine (high and low doses)
Number of subjects: 6
Study: 31107130

Group type: EXPERIMENTAL
Intervention: Target-shooting sport practiced once a week for 6 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Target-shooting sport
Number of subjects: 128
Study: 29578594

Group type: EXPERIMENTAL
Intervention: Early-intervention group (PCPs received CME and patients received mailers with educational materials and FOBT kits)
Number of subjects: 3120

Group type: COMPARATOR
Intervention: Delayed-intervention group (PCPs received no CME and patients received mailers in year 2)
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Overall effect of the mailer intervention (with or without CME)
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Impact on rates of colonoscopy or sigmoidoscopy
Number of subjects: 3120
Study: 26421384

Group type: EXPERIMENTAL
Intervention: Breakfast Consumption (BC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Breakfast Omission (BO)
Number of subjects: 8
Study: 24669314

Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise training (CONT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38
Study: 22208805

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg with 240 mL of ethanol 20%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymorphone CRF 40 mg with 240 mL of ethanol 20%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg with 240 mL of ethanol 40%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymorphone CRF 40 mg with 240 mL of ethanol 40%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER and CRF with ethanol (0 to 40%)
Number of subjects: 0
Study: 19843057

Group type: EXPERIMENTAL
Intervention: Anacetrapib
Number of subjects: 0
Study: 17620445

Group type: EXPERIMENTAL
Intervention: Diabetes personal trainer intervention (six self‐monitoring, goal‐setting, and problem‐solving sessions with trained nonprofessionals)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 81
Study: 15848604

Group type: COMPARATOR
Intervention: Tacrolimus (C0 monitoring)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Neoral (cyclosporine microemulsion, C2 monitoring)
Number of subjects: 700
Study: 11872346

Group type: EXPERIMENTAL
Intervention: Docetaxel (T)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and 5-fluorouracil (MF)
Number of subjects: 283
Study: 10640879

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (group A)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% (group B)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% (group C)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 67
Study: 8523236

Group type: EXPERIMENTAL
Intervention: D-[U-13C]glucose (100 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous 10% dextrose (D10W)
Number of subjects: 10
Study: 2311588

Group type: EXPERIMENTAL
Intervention: L-carnitine (L-C)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 7
Study: 7454128

Group type: EXPERIMENTAL
Intervention: Diet 2 (linoleic acid rich): carbohydrates 45 cal%, fats 40 cal% (one third linoleic acid), proteins 15 cal%.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor): carbohydrates 50 cal%, saturated fats 35 cal%, proteins 15 cal%.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Diet 2 (linoleic acid rich).
Number of subjects: 102

Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor).
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Diet 2 (linoleic acid rich) for females.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor) for females.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Diet 1 (linoleic acid poor) for males.
Number of subjects: 102
Study: 31678837

Group type: EXPERIMENTAL
Intervention: Full branding
Number of subjects: 9987

Group type: COMPARATOR
Intervention: Plain packaging or brand logo
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: Health warnings present
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: Edible gummies
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: 16-18 and 19-35 year-olds rating of edible gummies
Number of subjects: 9987
Study: 29071983

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (rehabilitation training only)
Number of subjects: 41
Study: 26415058

Group type: COMPARATOR
Intervention: 2‐session adolescent only (BI‐A)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: 2‐session adolescent and additional parent session (BI‐AP)
Number of subjects: 259
Study: 23659182

Group type: EXPERIMENTAL
Intervention: KiVa Antibullying Program
Number of subjects: 9912

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 9912
Study: 21795439

Group type: EXPERIMENTAL
Intervention: 4-course lunch consumed in 0.5 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: 4-course lunch consumed in 2 hours
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Changes in ghrelin concentrations
Number of subjects: 38
Study: 19577020

Group type: EXPERIMENTAL
Intervention: Mild Traumatic Brain Injury (MTBI)
Number of subjects: 4144

Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Disorder (PTSD)
Number of subjects: 4144

Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 4144

Group type: COMPARATOR
Intervention: MVC Injury Control
Number of subjects: 4144
Study: 17261652

Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel daily maintenance dose
Number of subjects: 40

Group type: COMPARATOR
Intervention: 75 mg clopidogrel daily maintenance dose
Number of subjects: 40
Study: 15121342

Group type: EXPERIMENTAL
Intervention: Divalproate (VPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (mood stabilizers plus anti-psychotic agents)
Number of subjects: 0
Study: 12081337

Group type: EXPERIMENTAL
Intervention: Parental presence at induction
Number of subjects: 118

Group type: COMPARATOR
Intervention: Parental absence at induction
Number of subjects: 118
Study: 9449494

Group type: EXPERIMENTAL
Intervention: HFA-cromolyn sodium
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: CFC-cromolyn sodium
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 7874944

Group type: EXPERIMENTAL
Intervention: Limited pulmonary rehabilitation program focused on coping strategies for shortness of breath (6-week treatment)
Number of subjects: 89

Group type: COMPARATOR
Intervention: General health education control group
Number of subjects: 89
Study: 2571815

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (weekly supportive group therapy with self-hypnosis for pain)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine oncological care (Control group)
Number of subjects: 86
Study: 930916

Group type: EXPERIMENTAL
Intervention: Total duration of oral contraceptive use
Number of subjects: 17942
Study: 30458499

Group type: EXPERIMENTAL
Intervention: High-deductible insurance plan
Number of subjects: 328899

Group type: COMPARATOR
Intervention: Low-deductible insurance plan
Number of subjects: 328899
Study: 26169870

Group type: COMPARATOR
Intervention: Salmon twice weekly (IG-F)
Number of subjects: 158

Group type: COMPARATOR
Intervention: ALA-rich rapeseed oil (IG-R)
Number of subjects: 158
Study: 25041550

Group type: EXPERIMENTAL
Intervention: Non-surgical mechanical periodontal treatment (test group, n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Delayed periodontal treatment (control group, n = 32)
Number of subjects: 64
Study: 22741027

Group type: EXPERIMENTAL
Intervention: Internet-based psychodynamic guided self-help treatment consisting of nine treatment modules with online therapist contact for 10 weeks.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Active control condition consisting of a structured support intervention with psychoeducation and scheduled weekly contacts online for 10 weeks.
Number of subjects: 92
Study: 20180933

Group type: EXPERIMENTAL
Intervention: Crushed tablets with concomitant meal
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Dispersible tablets with concomitant meal
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Crushed tablets with milk
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Dispersible tablets with milk
Number of subjects: 899

Group type: COMPARATOR
Intervention: Evaluable population (not food-related)
Number of subjects: 899
Study: 18288237

Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV‐05 vaginal suppository
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo vaginal suppository
Number of subjects: 30
Study: 15754230

Group type: EXPERIMENTAL
Intervention: Preoperative knee aspiration
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Preoperative arthroscopic biopsy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Preoperative arthroscopic biopsy and aspiration
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 86
Study: 12419098

Group type: EXPERIMENTAL
Intervention: Pemirolast potassium 0.1% ophthalmic solution
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 9860152

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Olanzapine 10 mg after 2 weeks of carbamazepine 200 mg BID
Number of subjects: 11
Study: 7630145

Group type: COMPARATOR
Intervention: Almokalant (12.8 mumol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2774884

Group type: EXPERIMENTAL
Intervention: Benzocaine spray
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (air spray)
Number of subjects: 8
Study: 897864

Group type: EXPERIMENTAL
Intervention: Vitamin C therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-leucine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single loading dose of L-tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single loading doses of L-kynurenine
Number of subjects: 0
Study: 31079282

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) - Exemestane and Letrozole
Number of subjects: 100
Study: 27472858

Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy 1 (850 nm Ga-Al-As laser)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy 2 (650 nm He-Ne, 785 ve 980 nm Ga-Al-As combined plaque laser)
Number of subjects: 49
Study: 26141942

Group type: EXPERIMENTAL
Intervention: HIIT (3 sets of 3‐min cycling with a 2‐min active rest between sets, 180 kcal)
Number of subjects: 26

Group type: COMPARATOR
Intervention: MICT (45 min, 360 kcal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both HIIT and MICT followed by a 4‐week LCDi
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 26
Study: 24011850

Group type: EXPERIMENTAL
Intervention: Illness management and recovery
Number of subjects: 118

Group type: COMPARATOR
Intervention: Problem solving control
Number of subjects: 118
Study: 21357809

Group type: EXPERIMENTAL
Intervention: Yearlong home-based exercise program (Exercise Plus Program)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 180
Study: 18276744

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day for 2 years followed by 10 mg/day for 1 year
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16563890

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 mcg/day
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 mcg/day
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520